WT1 and neoplasm: Following vaccination, WT2725 (a synthetic WT1 peptide) has potential to stimulate the host immune system to induce a CTL response against cancer cells that overexpress the WT1 protein, leading to cell lysis and preventing further tumor cell proliferation.